Melissa Cobleigh's Archive

Melissa Cobleigh completed her PhD in experimental pathology at Yale in the fall of 2011. She is currenly finishing up her work in the lab, researching a novel vaccine for the treatment of chronic hepatitis B virus, while she searches for a job. Melissa is originally from Maine and before coming to Yale attended Smith College where she received her bachelor’s degree in biochemistry. She recently "caught the running bug" after completing her first half marathon and hopes to compete in a triathlon as soon as she brushes up on her swimming skills. Melissa joined The Myeloma Beacon in June 2010.

Melissa Cobleigh has written 75 article(s) .

[ by | Dec 8, 2010 6:08 pm | Comments Off ]
Zometa May Improve Survival In Myeloma Patients (ASH 2010)

According to the results of a large Phase 3 clinical trial, Zometa increases overall and progression-free survival rates among multiple myeloma patients compared to Bonefos and is more effective in preventing bone loss and fractures.  Additonally, the trial found that inclusion of thalidomide as part of an induction regimen further improved responses. 

Dr. Gareth Morgan of the Royal Marsden Hospital in London presented the results, recently published in The Lancet (abstract), at the American Society of Hematology (ASH) annual …

Tags: , , , , , , , , , ,
Read the full story »
[ by | Nov 29, 2010 5:26 pm | Comments Off ]
Certain Chromosomal Abnormalities Negatively Impact The Outcome Of Revlimid-Dexamethasone Therapy In Relapsed And Refractory Multiple Myeloma Patients

According to a recent study, myeloma patients with the chromosomal abnormalities del(1p21) or del(17p) had shorter time to disease progression and lower overall survival rates while taking Revlimid-dexamethasone therapy than patients without those abnormalities.

Chromosomal abnormalities result from structural changes of the chromosome.  These changes may occur through deletions, insertions, duplications, or movement of chromosomal regions. Chromosomal abnormalities are considered high-risk factors in multiple myeloma and have been an area of intensive research because they may render patients less responsive …

Tags: , , , , , ,
Read the full story »
[ by | Nov 17, 2010 3:55 pm | Comments Off ]
Beacon NewsFlashes – November 17, 2010

NCI Initiates Study Of Novel Imaging Techniques To Identify Precursor Stages Of Myeloma – The National Cancer Institute (NCI) is recruiting patients for a study investigating the use of sensitive imaging technologies to identify progression of myeloma precursor diseases. There are currently no diagnostic tests available to determine whether an individual with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma will develop multiple myeloma. New and improved imaging techniques may help physicians better detect the progression of these …

Tags: , , , , , , , , , ,
Read the full story »
[ by | Nov 15, 2010 5:24 pm | One Comment ]
Velcade May Increase Bone Formation In Multiple Myeloma Patients

In addition to Velcade’s anti-myeloma effects, Velcade may also enhance bone formation, according to a Korean study of two multiple myeloma patients.

Based on the findings, the study investigators suggested that Velcade (bortezomib) treatment may be beneficial in patients with destructive bone disease.

However, in correspondence with the Myeloma Beacon, Dr. Chang-Ki Min, lead author of the study noted, “I believe that the incidental findings require additional studies. For example, clinical results such as response to Velcade or skeletal-related …

Tags: , , , ,
Read the full story »
[ by | Nov 9, 2010 2:36 pm | Comments Off ]
Growth Factor May Not Be Required Following Stem Cell Transplantation In Multiple Myeloma Patients

According to a recent study, omitting growth factor administration following stem cell transplantation results in fewer side effects and less and shorter hospitalization for multiple myeloma patients compared to those who do receive growth factors. In addition, the study authors found that there was little difference between the two groups in the repopulation of white blood cells following transplantation.

According to Dr. Morie Gertz, myeloma expert at the Mayo Clinic in Rochester, Minnesota and lead author of the study, the …

Tags: , , , , ,
Read the full story »